This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

Marzano A., Angelucci E., Astegiano M., Baratelli C., Biancone L., Bironzo P., et al. (2019). AISF position paper on HCV in immunocompromised patients. DIGESTIVE AND LIVER DISEASE, 51(1), 10-23 [10.1016/j.dld.2018.09.022].

AISF position paper on HCV in immunocompromised patients

Di Marco V.;Petta S.;Craxi A.;
2019-01-01

Abstract

This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.
http://www.elsevier.com/wps/find/journalbibliographicinfo.cws_home/623449/description#bibliographicinfo
Marzano A., Angelucci E., Astegiano M., Baratelli C., Biancone L., Bironzo P., et al. (2019). AISF position paper on HCV in immunocompromised patients. DIGESTIVE AND LIVER DISEASE, 51(1), 10-23 [10.1016/j.dld.2018.09.022].
File in questo prodotto:
File Dimensione Formato  
PETTA DLD 2019.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 1.33 MB
Formato Adobe PDF
1.33 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/401686
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
social impact